Redcare Achieves EUR222 Million in Prescription Revenue in Germany

In a recent announcement, Redcare has reported an impressive growth in its prescription revenue, reaching EUR222 million in Germany. The company, under the leadership of CEO Olaf Heinrich, has managed to triple its market share, reflecting a significant 27.2% increase in overall revenue compared to the previous half-year period.

For the second quarter alone, Redcare's revenue amounted to EUR709 million, marking a 26.4% increase. This growth trajectory is mirrored in the non-prescription (Non-Rx) segment, which expanded by 18.3% to EUR941 million in the first half of the year, with a 17% rise to EUR457 million in the second quarter.

A notable contributor to the Rx revenue surge is the company's aggressive marketing efforts targeted at the German market. During the second quarter, Redcare's prescription revenue in Germany more than doubled, climbing from EUR50 million to EUR114 million. Overall, the group's Rx revenue experienced a 48% growth, totaling EUR252 million.

Additionally, the number of active customers has increased by 400,000, bringing the total to 13.5 million. Over the past year, the company has welcomed 1.9 million new customers.

Heinrich emphasized the impact of the Card-Link procedure, which was introduced in May 2024, as a key factor in their success. He stated that the company's rapid growth and expansion confirm that they are only at the beginning of their journey.

To further stimulate customer engagement, Redcare is currently offering vouchers worth up to EUR10 for each prescription redeemed. This promotion allows customers to immediately apply the voucher to their orders, starting with the statutory co-payment, followed by any applicable fixed-price differences, and finally towards the purchase of additional over-the-counter (OTC) products. However, it is important to note that OTC medications and certain products are excluded from this offer, and no cash refunds or credits for unused residual amounts will be provided.

Looking ahead, Redcare aims to achieve an EBITDA margin exceeding 2% in the second quarter. The complete interim report for the first half of 2025 is scheduled for release on July 29, 2025.